pentobarbital will lessen the level or impact of celecoxib by affecting hepatic enzyme CYP2C9/ten metabolism. Small/Importance Unknown.
pentobarbital will reduce the level or impact of repaglinide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
Hypnotic doses of those barbiturates don't appear to significantly impair uterine exercise all through labor; whole anesthetic doses of barbiturates lessen the power and frequency of uterine contractions; administration of sedative-hypnotic barbiturates towards the mom during labor could bring about respiratory depression while in the new child
Watch Carefully (1)pentobarbital will enhance the degree or effect of clopidogrel by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
Avoid coadministration of ganaxolone with average or sturdy CYP3A4 inducers. If coadministration unavoidable, consider expanding ganaxolone dose; on the other hand, will not exceed greatest every day dose for fat.
pentobarbital will lower the level or effect of atorvastatin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will decrease the extent or impact of losartan by influencing hepatic enzyme CYP2C9/10 metabolism. Minor/Importance Unidentified.
pentobarbital boosts toxicity of ifosfamide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of. CYP3A4 inducers may possibly boost the metabolism of ifosfamide to its Lively website alkylating metabolites.
pentobarbital will reduce the level or effect of estradiol vaginal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
To reduce the potential for overdosage or the event of dependence, Restrict the prescribing and dispensing of sedative-hypnotic barbiturates, to the amount expected with the interval till the next appointment
pentobarbital will lower the level or effect of docetaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Mysterious.
pentobarbital will reduce the level or effect of amlodipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
Contraindicated (one)pentobarbital will lower the level or impact of lumefantrine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with sturdy CYP3A4 inducers may result in diminished serum concentrations and loss of antimalarial efficacy
pentobarbital decreases amounts of toremifene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe. CYP3A4 inducers boost rate of toremifene metabolism, decreasing the constant-state focus in serum.